<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01349751</url>
  </required_header>
  <id_info>
    <org_study_id>SiEC 197/2549</org_study_id>
    <nct_id>NCT01349751</nct_id>
  </id_info>
  <brief_title>Clinical Characteristics of Spinal Levobupivacaine: Hyperbaric Compared With Isobaric Solution</brief_title>
  <official_title>Clinical Characteristics of Spinal Levobupivacaine: Hyperbaric Compared With Isobaric Solution</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The authors would like to investigate the blocking characteristics, surgical quality and side
      effects of intrathecal levobupivacaine whether there are any differences between the
      hyperbaric and the isobaric formulation for gynaecologic surgeries which need higher block
      level than the urological surgeries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators study in the similar patients, give the same intervention except the
      baricity of levobupivacaine. The investigators record the level of sensory block and modified
      Bromage score for motor blockade.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to T4-dermatome sensory blockade</measure>
    <time_frame>30 minutes</time_frame>
    <description>to investigate specific blocking characteristics of intrathecal hyperbaric levobupivacaine compared with isobaric levobupivacaine for gynaecologic surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>side effects</measure>
    <time_frame>1 to 4 hours intraoperation plus within 2 hours in the recovery room</time_frame>
    <description>to investigate side effects of intrathecal hyperbaric levobupivacaine compared with isobaric levobupivacaine for gynaecologic surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Observation of Neuromuscular Block</condition>
  <condition>Disease (or Disorder); Gynecological</condition>
  <arm_group>
    <arm_group_label>isobaric levobupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>spinal isobaric levobupivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hyperbaric levobupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>hyperbaric levobupivacaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isobaric levobupivacaine</intervention_name>
    <description>0.42% either isobaric levobupivacaine 3 ml spinal injection once</description>
    <arm_group_label>isobaric levobupivacaine</arm_group_label>
    <other_name>Chirocaine, Abbott Laboratories, Nycomed Pharma AS, Norway</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hyperbaric levobupivacaine</intervention_name>
    <description>0.42% hyperbaric levobupivacaine 3 ml spinal injection once</description>
    <arm_group_label>hyperbaric levobupivacaine</arm_group_label>
    <other_name>Chirocaine, Abbott Laboratories, Nycomed Pharma AS, Norway</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA I-III, aged 18-70 yr, scheduled for elective gynaecologic surgery, (total
             abdominal hysterectomy (TAH), TAH with uni-/bilateral salpingo-oophorectomy (SO),
             uni-/bilateral ovarian cystectomy, or myomectomy

        Exclusion Criteria:

          -  contraindications for spinal block, body mass index (BMI) more than 35 kg/m2 and
             height less than 150 cm
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vimolluck - Sanansilp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Anesthesiology, Faculty of Medicine Siriraj Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine Siriraj Hospital, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2011</study_first_submitted>
  <study_first_submitted_qc>May 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2011</study_first_posted>
  <last_update_submitted>November 5, 2013</last_update_submitted>
  <last_update_submitted_qc>November 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mahidol University</investigator_affiliation>
    <investigator_full_name>Vimolluck Sanansilp</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>abdominal incision</keyword>
  <keyword>hyperbaric</keyword>
  <keyword>isobaric</keyword>
  <keyword>levobupivacaine</keyword>
  <keyword>spinal anaesthesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levobupivacaine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

